BIOHAVEN LTD (BHVN) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BHVN - VGG1110E1079 - Common Stock
BHVN Key Statistics, Chart & Performance
The current stock price of BHVN is 13.555 USD. In the past month the price increased by 18.62%. In the past year, price decreased by -67.28%.
BHVN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BHVN. When comparing the yearly performance of all stocks, BHVN is a bad performer in the overall market: 93.49% of all stocks are doing better.
BHVN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BHVN. Both the profitability and financial health of BHVN have multiple concerns.
BHVN Financial Highlights
Over the last trailing twelve months BHVN reported a non-GAAP Earnings per Share(EPS) of -7.6. The EPS increased by 18.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -190.68% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BHVN Forecast & Estimates
23 analysts have analysed BHVN and the average price target is 20.33 USD. This implies a price increase of 50% is expected in the next year compared to the current price of 13.555.
For the next year, analysts expect an EPS growth of 27.92% and a revenue growth -100% for BHVN
BHVN Ownership
About BHVN
Company Profile
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 256 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Company Info
BIOHAVEN LTD
215 Church Street
New Haven CONNECTICUT 06510 US
CEO: Vlad Coric
Employees: 256
Phone: 12034040410
BIOHAVEN LTD / BHVN FAQ
What does BHVN do?
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 256 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Can you provide the latest stock price for BIOHAVEN LTD?
The current stock price of BHVN is 13.555 USD. The price increased by 5.32% in the last trading session.
What is the dividend status of BIOHAVEN LTD?
BHVN does not pay a dividend.
What is the ChartMill technical and fundamental rating of BHVN stock?
BHVN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about BIOHAVEN LTD (BHVN) stock?
23 analysts have analysed BHVN and the average price target is 20.33 USD. This implies a price increase of 50% is expected in the next year compared to the current price of 13.555.
Can you provide the number of employees for BIOHAVEN LTD?
BIOHAVEN LTD (BHVN) currently has 256 employees.
Can you provide the market cap for BIOHAVEN LTD?
BIOHAVEN LTD (BHVN) has a market capitalization of 1.80B USD. This makes BHVN a Small Cap stock.